BridgeBio (BBIO) Pharma announced the Brazilian Health Regulatory Agency, ANVISA, has granted marketing authorization for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. “The ANVISA approval of Beyonttra marks an important step forward for Brazilian patients living with ATTR-CM. It is a particularly meaningful advance for patients living in Brazil who have long faced limited options for this progressive, life-threatening disease,” said Jonathan Fox, chief medical officer of BridgeBio Cardiorenal.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $102 from $95 at Truist
- Zemansky Reiterates Buy on BridgeBio, Nudges Price Target to $96 on Attruby Edge and Reduced Tafamidis Patent Overhang
- BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback
- Midday Fly By: OpenAI said to miss targets, Coca-Cola reports Q1 beat
- Pfizer Vyndamax settlement at lower end of expectations, says Morgan Stanley